A triple action CDK4/6-PI3K-BET inhibitor with augmented cancer cell cytotoxicity.
Burgoyne, A.M., Vann, K.R., Joshi, S., Morales, G.A., Vega, F.M., Singh, A., Pal, D., Merati, A.B., Kutateladze, T.G., Durden, D.L.(2020) Cell Discov 6: 49-49
- PubMed: 32793389 
- DOI: https://doi.org/10.1038/s41421-020-0181-z
- Primary Citation of Related Structures:  
6WW8
Organizational Affiliation: 
Division of Hematology-Oncology, Department of Medicine, Moores Cancer Center, University of California San Diego, La Jolla, CA USA.